Evaluation of the effi cacy of rebamipide in functional dyspepsia and irritable bowel syndrome treatment

Purpose: to evaluate the efficacy and safety of the use of rebamipide (Rebamipide-SZ, Severnaya Zvezda NAO) during 8-week therapy in patients with functional dyspepsia (FD) and/or irritable bowel syndrome (IBS). Materials and methods: 60 patients of both sexes aged 18 to 40 years with confirmed FD and/or IBS were examined. All patients received basic therapy for functional gastrointestinal disease. Patients of the main group were additionally prescribed rebamipide 100 mg 3 times a day. All patients were tested according to the 7x7 questionnaire to assess the severity of FD and IBS symptoms; the severity of anxiety and depression symptoms was assessed according to the Hospital Anxiety and Depression Scale (HADS); the level of zonulin in blood was determined by the ELISA method at baseline and after 8 weeks of therapy. Results: in the main group of patients, taking rebamipide led to a more pronounced decrease in the average score on the scales of the 7x7 questionnaire, such as feeling full (0 [0; 0] points vs 1 [1; 1] points, p=0.000), early satiety (0 [0; 0] points vs 0.5 [0; 1] points, p=0.005), bloating (0 [0; 2] points vs 2 [2; 2] points, p=0.001). Only patients of the main group showed a significant decrease in blood zonulin levels both in the FD subgroup (Δ%= -49%) and in the FD+IBS subgroup (Δ%= -20.85%). Conclusions: the use of rebamipide at the dose of 100 mg 3 times a day for 8 weeks as part of the basic therapy of patients with functional dyspepsia and/ord irritable bowel syndrome leads to a statistically significant improvement in the clinical condition of patients and a significant decrease in the level of zonulin in blood serum.

functional gastrointestinal disorders, functional dyspepsia, irritable bowel syndrome, overlap syndrome, leaky epithelial syndrome, zonulin, rebamipide

1. Simanenkov V.I., Maev I. V., Tkacheva O. N., et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758. (In Russ.) doi: 10.15829/1728-8800-2021-2758. @@Симаненков В. И., Маев И. В., Ткачева О. Н., Алексеенко С. А., и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758. doi: 10.15829/1728-8800-2021-2758.

2. Hanning N., Edwinson A. L., Ceuleers H., Peters S. A., De Man J. G., Hassett L. C., De Winter B. Y., Grover M.Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Therap Adv Gastroenterol. 2021 Feb 24;14:1756284821993586. doi: 10.1177/1756284821993586. PMID: 33717210; PMCID: PMC7925957.

3. Tack J., Schol J., Van den Houte K., Huang I. H., Carbone F. Paradigm Shift: Functional Dyspepsia-A “Leaky Gut” Disorder? Am J Gastroenterol. 2021 Feb 1;116(2):274-275. doi: 10.14309/ajg.0000000000001077. PMID: 33298703

4. Von Wulffen M., Talley N. J., Hammer J., et al. Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Dig Dis Sci 2019; 64 (2): 480-6. doi: 10.1007/s10620-018-5343-6.

5. Fukui H. Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? Inflamm Intest Dis. 2016 Oct;1(3):135-145. doi: 10.1159/000447252. Epub 2016 Jul 20. PMID: 29922669; PMCID: PMC5988153.

6. Ng Q.X., Soh A. Y.S., Loke W., Lim D. Y., Yeo W. S. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res. 2018 Sep 21;11:345-349. doi: 10.2147/JIR.S174982. PMID: 30288077; PMCID: PMC6159811.

7. Calleja-Conde J., Echeverry-Alzate V., Bühler K. M., et al. The Immune System through the Lens of Alcohol Intake and Gut Microbiota.Int J Mol Sci. 2021 Jul 13;22(14):7485. doi: 10.3390/ijms22147485.

8. Leech B., Schloss J., Steel A. Treatment Interventions for the Management of Intestinal Permeability: A Cross-Sectional Survey of Complementary and Integrative Medicine Practitioners. J Altern Complement Med. 2019 Jun;25(6):623-636. doi: 10.1089/acm.2018.0374.

9. Fortea M., Albert-Bayo M., Abril-Gil M., et al. Present and Future Therapeutic Approaches to Barrier Dysfunction. Front. Nutr. 2021; 8:718093. doi: 10.3389/fnut.2021.718093.

10. Gopalakrishnan S., Durai M., Kitchens K., Tamiz A. P., Somerville R., Ginski M., et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. (2012) 35:86-94. doi: 10.1016/j.peptides.2012.02.015.

11. Sturgeon C., Fasano A. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers. (2016) 4: e1251384. doi: 10.1080/21688370.2016.1251384.

12. Arakawa T., Higuchi K., Fujiwara Y., et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005 Oct;50 Suppl 1: S3-S11. doi: 10.1007/s10620-005-2800-9. PMID: 16184418.

13. Andreev D. N., Maev I. V. Rebamipide: evidence base for use in gastroenterology. Terapevticheskii arkhiv. 2020; 92 (12): 97-104. doi: 10.26442/00403660.2020.12.200455 @@Андреев Д. Н., Маев И. В. Ребамипид: доказательная база применения в гастроэнтерологии. Терапевтический архив. 2020; 92 (12): 97-104. doi: 10.26442/00403660.2020.12.200455.

14. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3):261-70. doi: 10.1586/egh.10.25.

15. Song D.U., Ryu M. H., Chay K. O., et al. Effect of rebamipide on the glycosaminoglycan content of the ulcerated rat stomach. Fundam Clin Pharmacol. 1998;12(5):546-52. doi: 10.1111/j.1472-8206.1998.tb00984.x.

16. Suzuki T., Yoshida N., Nakabe N., et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci. 2008; 106 (3): 469-77. doi: 10.1254/jphs.fp0071422.

17. Kamada T., Sato M., Tokutomi T., et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int. 2015;2015:865146. doi: 10.1155/2015/865146.

18. Tarnawski A.S., Chai J., Pai R., Chiou S. K. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004 Feb;49(2):202-9. doi: 10.1023/b: ddas.0000017439.60943.5c.

19. Ivashkin V. T., Maev I. V., Tsar’kov P.V., et al. Diagnosis and Treatment of Peptic Ulcer in Adults (Clinical Guidelines of the Russian Gastroenterological Association, Russian Society of Colorectal Surgeons and the Russian Endoscopic Society).Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(1):49-70. (In Russ.) doi: 10.22416/1382-4376-2020-30-1-49-70 @@Ивашкин В. Т., Маев И. В., Царьков П. В., и др. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(1):49-70. doi: 10.22416/1382-4376-2020-30-1-49-70

20. Lazebnik L.B., Golovanova E. V., Alekseenko S. A., et al. Recommendations for the prevention and treatment of esophago-gastro-entero-colopathy induced by nonsteroidal antiinflammatory drugs “NSAID”. Experimental and Clinical Gastroenterology. 2018;(3):4-18. (In Russ.) @@Лазебник Л. Б., Голованова Е. В., Алексеенко С. А., Бакулина Н. В., и др. Рекомендации по профилактике и лечению эзофаго-гастро-энтеро-колопатий, индуцированных нестероидными противовоспалительными препаратами (НПВП). Экспериментальная и клиническая гастроэнтерология. 2018;151(3): 4-18.

21. Karateev A. E., Nasonov E. L., Yakhno N. N., et al. Clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice». Modern Rheumatology Journal. 2015;9(1):4-23. (In Russ.) doi: 10.14412/1996-7012-2015-1-4-23 @@Каратеев А. Е., Насонов Е. Л., Яхно Н. Н., Ивашкин В. Т., и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;9(1):4-23. doi: 10.14412/1996-7012-2015-1-4-23

22. Ivashkin V.T., Mayev I. V., Lapina T. L., et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Ross z gastroenterol gepatol koloproktol. 2018; 28(1):55-70. doi: 10.22416/1382-4376-2018-28-1-55-70 @@Ивашкин В. Т., Маев И. В., Лапина Т. Л., Шептулин А. А., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос журн гастроэнтерол гепатол колопроктол 2018; 28(1):55-70. doi: 10.22416/1382-4376-2018-28-1-55-70.

23. Grinevich V.B., Kravchuk Yu.A., Ped V. I., et al. Management of patients with digestive diseases during the COVID-19 pandemic: Clinical Practice Guidelines by the Gastroenterological Scientifi c Society of Russia. Experimental and Clinical Gastroenterology. 2020;179(7): 4-51. (In Russ.) doi: 10.31146/1682-8658-ecg-179-7-4-51 @@Гриневич В. Б., Кравчук Ю. А., Педь В. И., и др. Ведение пациентов с заболеваниями органов пищеварения в период пандемии COVID-19. Клинические рекомендации Научного общества гастроэнтерологов России. Экспериментальная и клиническая гастроэнтерология. 2020;179(7): 4-51. doi: 10.31146/1682-8658-ecg-179-7-4-51.

24. Jaafar M.H., Safi S. Z., Tan M. P., et al. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2018 May;63(5):1250-1260. doi: 10.1007/s10620-017-4871-9.

25. Ivashkin V. T., Sheptulin A. A., Poluektova E. A., et al. Potential of «7×7» (7 symptoms per 7 days) questionnaire in assessment of symptom dynamics of functional dyspepsia and irritable bowel syndrome. Ross z gastroenterol gepatol koloproktol. 2016;26(3):24-33. doi: 10.22416/1382-4376-2016-26-3-24-33 @@Ивашкин В. Т., Шептулин А. А., Полуэктова Е. А., Рейхарт Д. В., Белостоцкий А. В., Дроздова А. А., Арнаутов В. С. Возможности применения Опросника «7×7» (7 симптомов за 7 дней) для оценки динамики симптомов функциональной диспепсии и синдрома раздраженного кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(3):24-33. doi: 10.22416/1382-4376-2016-26-3-24-33

26. Fasano A. All disease begins in the (leaky) gut: role of zonulin mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Res. 2020;9: F1000 Faculty Rev-69. doi: 10.12688/f1000research.20510.1.

27. Singh P., Silvester J., Chen X., et al. Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D. United European Gastroenterology Journal. 2019:205064061982641. doi: 10.1177/2050640619826419.

28. Kindt S., Tack J. Impaired gastric accommodation and its role in dyspepsia. Gut. 2006 Dec;55(12):1685-91. doi: 10.1136/gut.2005.085365. Epub 2006 Jul 19.

29. Lee K.J., Kim J. H., Cho S. W. Dyspeptic symptoms associated with hypersensitivity to gastric distension induced by duodenal acidification. J Gastroenterol Hepatol. 2006;21(3):515-520. doi:10.1111/j.1440-1746.2005.03976.x.

30. Page A.J., Li H. Meal-Sensing Signaling Pathways in Functional Dyspepsia. Front Syst Neurosci. 2018 Apr 5;12:10. doi: 10.3389/fnsys.2018.00010.

31. Walker MM, Talley NJ, Prabhakar M, Pennaneac’h CJ, Aro P, Ronkainen J, Storskrubb T, Harmsen WS, Zinsmeister AR, Agreus L. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 2009 Apr 1;29(7):765-73. doi: 10.1111/j.1365-2036.2009.03937.x.

32. Talley N.J., Ford A. C. Functional Dyspepsia. N Engl J Med. 2015 Nov 5;373(19):1853-63. doi: 10.1056/NEJMra1501505.

33. Vanheel H., Vicario M., Vanuytsel T., et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014 Feb;63(2):262-71. doi: 10.1136/gutjnl-2012-303857.

34. Fan K., Talley N. J. Functional dyspepsia and duodenal eosinophilia: A new model. J Dig Dis. 2017;18(12):667-677. doi:10.1111/1751-2980.12556.

35. Wang W., Uzzau S., Goldblum S. E., Fasano A. Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci. 2000;113 Pt 24:4435-4440. doi:10.1242/jcs.113.24.4435.

36. Silva A.C., Lobo J. M.S. Cytokines and Growth Factors. Adv Biochem Eng Biotechnol. 2020;171:87-113. doi: 10.1007/10_2019_105.

37. Arakawa T., Kobayashi K., Yoshikawa T., Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig. Dis. Sci. 1998 Sep;43(9 Suppl):5S-13S. PMID: 9753220.

38. Markovic M., Zur M., Dahan A., Cvijić S. Biopharmaceutical characterization of rebamipide: The role of mucus binding in regional-dependent intestinal permeability. Eur J Pharm Sci. 2020 Sep 1;152:105440. doi: 10.1016/j.ejps.2020.105440.

39. Bennet S.M., Polster A., Törnblom H., et al. Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome. Am J Gastroenterol. 2016 Aug;111(8):1165-76. doi: 10.1038/ajg.2016.223.

40. Oliviero S., Cortese R. The human haptoglobin gene promoter: interleukin-6-responsive elements interact with a DNA-binding protein induced by interleukin-6. EMBO J. 1989 Apr;8(4):1145-51. Erratum in: EMBO J. 1989 Jul;8(7):2121. PMID: 2787245; PMCID: PMC400927.